Liposomal Bupivacaine for Lumbar Spinal Stenosis
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: University of Colorado, Denver
No Placebo Group
Prior Safety Data
Approved in 1 jurisdiction
Trial Summary
What is the purpose of this trial?Evaluate the benefit of using liposomal bupivicaine in lumbar laminectomies in terms of length of stay, IV narcotic use, 30-day narcotic use, visual analog score (VAS) and 30-day readmissions
Eligibility Criteria
Adults over 18 with lumbar spinal stenosis who haven't had previous surgery at the affected level and don't require a fusion procedure. It's not for those under 18, pregnant or breastfeeding individuals, prisoners, patients with daily high-dose opioid use, or if there are other health issues that make surgery too risky.Treatment Details
The trial is testing whether liposomal bupivacaine can improve outcomes after lumbar laminectomy surgeries. It looks at how long patients stay in the hospital, their need for IV and oral narcotics post-surgery, pain levels using VAS scores, and readmission rates within 30 days.
2Treatment groups
Active Control
Group I: Liposomal BupivicaineActive Control1 Intervention
Treatment with liposomal bupivicaine
Group II: Standard Local AnesthesticActive Control1 Intervention
Treatment with Standard Local Anesthestic
Liposomal Bupivacaine is already approved in United States for the following indications:
🇺🇸 Approved in United States as EXPAREL for:
- Postsurgical local analgesia via infiltration in adults
- Regional analgesia via interscalene brachial plexus nerve block in adults
Find a clinic near you
Research locations nearbySelect from list below to view details:
University of Colorado Anschutz Medical CampusAurora, CO
Loading ...
Who is running the clinical trial?
University of Colorado, DenverLead Sponsor